| 0.783 -0.137 (-14.9%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.41  |
1-year : | 1.72 |
| Resists | First : | 1.2 |
Second : | 1.48 |
| Pivot price | 1.02 |
|||
| Supports | First : | 0.76 |
Second : | 0.64 |
| MAs | MA(5) : | 0.95 |
MA(20) : | 1.07 |
| MA(100) : | 1.81 |
MA(250) : | 5.83 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 1.4 |
D(3) : | 6.1 |
| RSI | RSI(14): 25.6 |
|||
| 52-week | High : | 22.36 | Low : | 0.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SLXN ] has closed below the lower bollinger band by 18.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ SLXN ] is to continue within current trading range. It is unclear right now based on current values. 49.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.93 - 0.94 | 0.94 - 0.94 |
| Low: | 0.76 - 0.76 | 0.76 - 0.77 |
| Close: | 0.77 - 0.78 | 0.78 - 0.79 |
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Sat, 11 Apr 2026
SLXNW SEC Filings - Silexion Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Tue, 24 Mar 2026
Pancreatic cancer drug SIL204 gets Israel approval for human trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 8.2 (%) |
| Held by Institutions | 4.2 (%) |
| Shares Short | 50 (K) |
| Shares Short P.Month | 45 (K) |
| EPS | -8.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -144.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.09 |
| PEG Ratio | 0 |
| Price to Book value | 0.94 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|